Am J Blood Res 2012;2(2):86-97
Review Article
Advances and application of radioimmunotherapy in non-hodgkin lymphoma
Patrick L. Stevens, Olalekan Oluwole, Nishitha Reddy
Division of Hematology and Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN
Received January 13, 2012; accepted February 30, 2012; Epub April 22, 2012; Published June 15, 2012
Abstract: The activity of radio-immuno conjugate in Non-Hodgkin Lymphoma (NHL) has resulted in FDA approval of two
antibodies, Y90 Ibritumomab tiuxetan and I131 tositumomab. Both these agents target CD20, a receptor widely expressed in
B-Cell NHL. These immunoconjugates deliver their radioactive payload to the malignant clone in the bone marrow and lymph
node. Their use has been associated with modest improvement in survival end points among several lymphoma histologies.
The promising effect on disease control as well as their efficacy in disease relapse is encouraging in low grade lymphoma.
Radioimmunotherapy (RIT) is increasingly being explored in the setting of consolidation as well as conditioning regimens
prior to stem cell transplantation. Here, we summarize the clinical use, complications and future applications of RIT in NHL.
(AJBR1201001).
Keywords: Radioimmunotherapy, non-hodgkin lymphoma, stem cell transplantation, CD20 target
Address all correspondence to:
Dr. Nishitha Reddy
Division of Hematology and Oncology
Department of Medicine
Vanderbilt University Medical Center
1301 Medical Center Drive, 3927 TVC
Nashville, TN 37232, USA.
Tel: 615-936-0381; Fax: 615-936-1812
E-mail: Nishitha.Reddy@Vanderbilt.Edu
Review Article
Advances and application of radioimmunotherapy in non-hodgkin lymphoma
Patrick L. Stevens, Olalekan Oluwole, Nishitha Reddy
Division of Hematology and Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN
Received January 13, 2012; accepted February 30, 2012; Epub April 22, 2012; Published June 15, 2012
Abstract: The activity of radio-immuno conjugate in Non-Hodgkin Lymphoma (NHL) has resulted in FDA approval of two
antibodies, Y90 Ibritumomab tiuxetan and I131 tositumomab. Both these agents target CD20, a receptor widely expressed in
B-Cell NHL. These immunoconjugates deliver their radioactive payload to the malignant clone in the bone marrow and lymph
node. Their use has been associated with modest improvement in survival end points among several lymphoma histologies.
The promising effect on disease control as well as their efficacy in disease relapse is encouraging in low grade lymphoma.
Radioimmunotherapy (RIT) is increasingly being explored in the setting of consolidation as well as conditioning regimens
prior to stem cell transplantation. Here, we summarize the clinical use, complications and future applications of RIT in NHL.
(AJBR1201001).
Keywords: Radioimmunotherapy, non-hodgkin lymphoma, stem cell transplantation, CD20 target
Address all correspondence to:
Dr. Nishitha Reddy
Division of Hematology and Oncology
Department of Medicine
Vanderbilt University Medical Center
1301 Medical Center Drive, 3927 TVC
Nashville, TN 37232, USA.
Tel: 615-936-0381; Fax: 615-936-1812
E-mail: Nishitha.Reddy@Vanderbilt.Edu
| AJBR Copyright © 2011-present, All rights reserved. Published by e-Century Publishing Corporation, Madison, WI 53711, USA |
 |  |  |  |  |  |  |